|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
Statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ramchandren R and Schiffer C: Dasatinib in
the treatment of imatinib refractory chronic myeloid leukemia.
Biologics. 3:205–214. 2009.PubMed/NCBI
|
|
3
|
Sawyers CL: Chronic Myeloid Leukemia. N
Engl J Med. 340:1330–1340. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jabbour E, Cortes J and Kantarjian H:
Treatment selection after imatinib resistance in chronic myeloid
leukemia. Target Oncol. 4:3–10. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nowell PC and Hungerford DA: A minute
chromosome in human chronic granulocytic leukemia. Science.
142:14971960.
|
|
6
|
Rowley JD: Letter: A new consistent
chromosomal abnormality in chronic myelogenous leukaemia identified
by quinacrine fluorescence and Giemsa staining. Nature.
243:290–293. 1973. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mandanas R, Leibowitz D, Gharehbaghi K,
Tauchi T, Burgess G, Miyazawa K, Jayaram H and Boswell H: Role of
p21 RAS in p210 bcr-abl transformation of murine myeloid cells.
82:1838–1847. 1993.
|
|
8
|
Okuda K, Matulonis U, Salgia R, Kanakura
Y, Druker B and Griffin J: Factor independence of human myeloid
leukemia cell lines is associated with increased phosphorylation of
the proto-oncogene Raf-1. Exp Hematol. 22:1111–1117.
1994.PubMed/NCBI
|
|
9
|
Raitano AB, Halpern JR, Hambuch TM and
Sawyers CL: The Bcr-Abl leukemia oncogene activates Jun kinase and
requires Jun for transformation. Proc Natl Acad Sci USA.
92:11746–11750. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sawyers CL, Callahan W and Witte ON:
Dominant negative MYC blocks transformation by ABL oncogenes. Cell.
70:901–910. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shuai K, Halpern J, ten Hoeve J, Rao X and
Sawyers CL: Constitutive activation of STAT5 by the BCR-ABL
oncogene in chronic myelogenous leukemia. Oncogene. 13:247–254.
1996.PubMed/NCBI
|
|
12
|
Tan J, Cang S, Seiter K, Primanneni S,
Ahmed N, Mathews T and Liu D: t(3;9;22) 3-way chromosome
translocation in chronic myeloid leukemia is associated with poor
prognosis. Cancer Invest. 27:718–722. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Quintás-Cardama A and Cortes JE: Chronic
myeloid leukemia: Diagnosis and treatment. Mayo Clin Proc.
81:973–988. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jabbour E and Kantarjian H: Chronic
myeloid leukemia: 2014 update on diagnosis, monitoring, and
management. Am J Hematol. 89:547–556. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Angstreich GR, Smith BD and Jones RJ:
Treatment options for chronic myeloid leukemia: Imatinib versus
interferon versus allogeneic transplant. Curr Opin Oncol. 16:95–99.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gora-Tybor J and Robak T: Targeted drugs
in chronic myeloid leukemia. Curr Med Chem. 15:3036–3051. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Emadi A, Jones RJ and Brodsky RA:
Cyclophosphamide and cancer: Golden anniversary. Nat Rev Clin
Oncol. 6:638–647. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wu J and Gentry R: gcrma: Background
adjustment using sequence information. R package. version
2.46.0.
|
|
19
|
Gentleman R, Carey V, Huber W and Hahne F:
genefilter: genefilter: Methods for filtering genes from microarray
experiments. R package. version 1.56.0.
|
|
20
|
Smyth GK: Limma: Linear models for
microarray data. Gentleman R, Carey V, Dudoit S, Irizarry R and
Huber W: Bioinformatics and Computational Biology Solutions Using R
and Bioconductor New York: Springer; pp. 397–420. 2005, View Article : Google Scholar
|
|
21
|
Tavazoie S, Hughes JD, Campbell MJ, Cho RJ
and Church GM: Systematic determination of genetic network
architecture. Nat Genet. 22:281–285. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Carlson M: GO.db: A set of annotation maps
describing the entire Gene Ontology. R package. version 3.0.0.
|
|
23
|
Carlson M: KEGG.db: A set of annotation
maps for KEGG. R package. version 3.2.3.
|
|
24
|
Tenenbaum D: KEGGREST: Client-side REST
access to KEGG. R package. version 1.14.1.
|
|
25
|
Prasad Keshava TS, Goel R, Kandasamy K,
Keerthikumar S, Kumar S, Mathivanan S, Telikicherla D, Raju R,
Shafreen B, Venugopal A, et al: Human protein reference
database-2009 update. Nucleic Acids Res. 37:(Database Issue).
D767–D772. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chatr-aryamontri A, Breitkreutz BJ,
Heinicke S, Boucher L, Winter A, Stark C, Nixon J, Ramage L, Kolas
N, O'Donnell L, et al: The BioGRID interaction database: 2013
update. Nucleic Acids Res. 41:(Database Issue). D816–D823. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
McDowall MD, Scott MS and Barton GJ: PIPs:
Human protein-protein interaction prediction database. Nucleic
Acids Res. 37:(Database Issue). D651–D656. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Smoot ME, Ono K, Ruscheinski J, Wang PL
and Ideker T: Cytoscape 2.8: New features for data integration and
network visualization. Bioinformatics. 27:431–432. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Colvin O: An overview of cyclophosphamide
development and clinical applications. Curr Pharm Des. 5:555–560.
1999.PubMed/NCBI
|
|
31
|
Sládek NE: Leukemic cell insensitivity to
cyclophosphamide and other oxazaphosphorines mediated by aldehyde
dehydrogenase(s). Clinically Relevant Resistance in Cancer
Chemotherapy. Springer; pp. 161–175. 2002, View Article : Google Scholar
|
|
32
|
Russo JE, Hilton J and Colvin OM: The role
of aldehyde dehydrogenase isozymes in cellular resistance to the
alkylating agent cyclophosphamide. Prog Clin Biol Res. 290:65–79.
1989.PubMed/NCBI
|
|
33
|
Moreb J, Muhoczy D, Ostmark B and Zucali
J: RNAi-mediated knockdown of aldehyde dehydrogenase class-1A1 and
class-3A1 is specific and reveals that each contributes equally to
the resistance against 4-hydroperoxycyclophosphamide. Cancer
Chemother Pharmacol. 59:127–136. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Plebuch M, Soldan M, Hungerer C, Koch L
and Maser E: Increased resistance of tumor cells to daunorubicin
after transfection of cDNAs coding for anthracycline inactivating
enzymes. Cancer Lett. 255:49–56. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kadomatsu K and Muramatsu T: Midkine and
pleiotrophin in neural development and cancer. Cancer Lett.
204:127–143. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kang HC, Kim IJ, Park HW, Jang SG, Ahn SA,
Yoon SN, Chang HJ, Yoo BC and Park JG: Regulation of MDK expression
in human cancer cells modulates sensitivities to various anticancer
drugs: MDK overexpression confers to a multi-drug resistance.
Cancer Lett. 247:40–47. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xu YY, Mao XY, Song YX, Zhao F, Wang ZN,
Zhang WX, Xu HM and Jin F: Midkine confers Adriamycin resistance in
human gastric cancer cells. Tumor Biol. 33:1543–1548. 2012.
View Article : Google Scholar
|
|
38
|
Mishra S, Siddique H and Saleem M: S100A4
calcium-binding protein is key player in tumor progression and
metastasis: Preclinical and clinical evidence. Cancer Metastasis
Rev. 31:163–172. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mahon PC, Baril P, Bhakta V, Chelala C,
Caulee K, Harada T and Lemoine NR: S100A4 Contributes to the
suppression of BNIP3 expression, chemoresistance and inhibition of
apoptosis in pancreatic cancer. Cancer Res. 67:6786–6795. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hekmat O, Munk S, Fogh L, Yadav R,
Francavilla C, Horn H, Würtz SØ, Schrohl AS, Damsgaard B, Rømer MU,
et al: TIMP-1 increases expression and phosphorylation of proteins
associated with drug resistance in breast cancer cells. J Proteome
Res. 12:4136–4151. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Rivera J and Olivera A: A current
understanding of Fc epsilon RI-dependent mast cell activation. Curr
Allergy Asthma Rep. 8:14–20. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yu H and Jove R: The STATs of cancer-new
molecular targets come of age. Nat Rev Cancer. 4:97–105. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Schaller-Schönitz M, Barzan D, Williamson
AJ, Griffiths JR, Dallmann I, Battmer K, Ganser A, Whetton AD,
Scherr M and Eder M: BCR-ABL Affects STAT5A and STAT5B
differentially. PLoS One. 9:e972432014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hong X, Chen G, Wang M, Lou C, Mao Y, Li Z
and Zhang Y: STAT5a-targeting miRNA enhances chemosensitivity to
cisplatin and 5-fluorouracil in human colorectal cancer cells. Mol
Med Rep. 5:1215–1219. 2012.PubMed/NCBI
|
|
45
|
Saito YD, Jensen AR, Salgia R and Posadas
EM: Fyn: A novel molecular target in cancer. Cancer. 116:1629–1637.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Elias D, Vever H, Lankholm AV, Gjerstorff
MF, Yde CW, Lykkesfeldt AE and Ditzel HJ: Gene expression profiling
identifies FYN as an important molecule in tamoxifen resistance and
a predictor of early recurrence in patients treated with endocrine
therapy. Oncogene. 34:1919–1927. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Fenouille N, Puissant A, Dufies M, Robert
G, Jacquel A, Ohanna M, Deckert M, Pasquet JM, Mahon FX, Cassuto
JP, et al: Persistent activation of the Fyn/ERK kinase signaling
axis mediates imatinib resistance in chronic myelogenous leukemia
cells through upregulation of intracellular SPARC. Cancer Res.
70:9659–9670. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Riccaboni M, Bianchi I and Petrillo P:
Spleen tyrosine kinases: Biology, therapeutic targets and drugs.
Drug Discov Today. 15:517–530. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Gioia R, Leroy C, Drullion C, Lagarde V,
Etienne G, Dulucq S, Lippert E, Roche S, Mahon FX and Pasquet JM:
Quantitative phosphoproteomics revealed interplay between Syk and
Lyn in the resistance to nilotinib in chronic myeloid leukemia
cells. Blood. 118:2211–2221. 2011. View Article : Google Scholar : PubMed/NCBI
|
